All In Biotech

Drug Trial Radar · NCT03673943

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

An Open-label, Single-dose, Single Arm, Single-center Clinical Trial of 64Cu(Copper)-DOTATATE (NETMedix™) PET-CT Scan for Imaging Patients With Known or Suspected Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)

Last checked: Nov 20, 2026Latest source record: Dec 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

63

Actual

Start

Aug 23, 2018

Primary completion

Mar 23, 2019

Study completion Aug 7, 2019

Sponsor

Lead sponsor
Radiomedix, Inc.Industry
Sponsor type
Industry
First posted
Sep 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, single-dose, single-arm, single-center imaging study using DOTATATE peptide, labelled with the 64Cu tracer.

Conditions

  • Neuroendocrine Tumors

Interventions

  • 64Cu-DOTATATEDrug

    Detection of somatostatin positive lesions in NET

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity of 64Cu-DOTATATE PET-CT Imaging for Detection of Somatostatin Receptor Positive SSTR (+) TumorTime frame: 12 months
  2. Specificity of 64Cu- DOTATATE PET/CT Imaging for Detection of Neuroendocrine TumorTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Excel Diagnostics and Nuclear Oncology Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.